Tag Archive for: Dr John Maher

Leucid Bio provides business update and outlook for 2023

/in

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]

Read more

Leucid Bio Chief Scientific Officer John Maher publishes new research on pCAR technology

/in

New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets and target combinations in pre-clinical liquid and solid tumour cell lines/models John Maher has been an early pioneer of CAR T-cell immunotherapy with a focus on solid tumours London, UK […]

Read more